Cargando…
A Cyclic Peptide Epitope of an Under-Explored VEGF-B Loop 1 Demonstrated In Vivo Anti-Angiogenic and Anti-Tumor Activities
Pathological angiogenesis is mainly initiated by the binding of abnormal expressed vascular endothelial growth factors (VEGFs) to their receptors (VEGFRs). Blocking the VEGF/VEGFR interaction is a clinically proven treatment in cancer. Our previous work by epitope scan had identified cyclic peptides...
Autores principales: | Wang, Lei, Xu, Meng, Hu, Haofeng, Zhang, Lun, Ye, Fei, Jin, Jia, Fang, Hongming, Chen, Jian, Chen, Guiqian, Broussy, Sylvain, Vidal, Michel, Lv, Zhengbing, Liu, Wang-Qing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511632/ https://www.ncbi.nlm.nih.gov/pubmed/34658874 http://dx.doi.org/10.3389/fphar.2021.734544 |
Ejemplares similares
-
Anti-angiogenic alternatives to VEGF blockade
por: Khan, Kabir A., et al.
Publicado: (2015) -
Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway
por: Itatani, Yoshiro, et al.
Publicado: (2018) -
Anti-angiogenic effects of VEGF stimulation on endothelium deficient in phosphoinositide recycling
por: Stratman, Amber N., et al.
Publicado: (2020) -
Anti-VEGF-A Affects the Angiogenic Properties of Tumor-Derived Microparticles
por: Munster, Michal, et al.
Publicado: (2014) -
Anti-Angiogenic Effect of Asperchalasine A Via Attenuation of VEGF Signaling
por: Park, Jun Yeon, et al.
Publicado: (2019)